Biotechnologyin Bavaria 2008

3

ImprintEditorial staff: Dr. Georg Kääb, Dr. Petra Burgstaller

Data collection: Dr. Petra Burgstaller, Sabine Jordan

Company Profiles: Ivonne Wagner, Lina Paulenz

Layout-Design: aimcom, Munich, www.aimcom.de

Illustration: dedicated to Charles Darwin in the

“Darwin-Year 2009”

Contact

Prof. Dr. Horst Domdey, Managing Director

Spokesman of the Bavarian Biotechnology Cluster

Nicola Schumacher and Dr. Mathias Lamparter,

Cluster Manager

The Bavarian and the Munich Biotechnology Cluster

are managed by:

BioM Biotech Cluster Development GmbH

Am Klopferspitz 19

D-82152 Martinsried

Phone: +49 (0)89-89 96 79-0

Fax: +49 (0)89-89 96 79-79

E-Mail: info@bio-m.org

Internet: www.bio-m.org

The layout, graphics and other contents of this brochure

of the Bavarian Biotechnology Cluster are protected by

copyright law.

4

ContentWelcome notes/Preface 06-07

Martin Zeil – Bavarian Minister of Economic Affairs,

Infrastructure, Transport and Technology 06

Prof. Dr. Horst Domdey –

Managing Director, Bavarian Biotechnology Cluster 07

Introduction 09

The Companies in the Bavarian Biotechnology Cluster 11-12

Current Status 11-12

Employment 13

Jobs in biotechnology companies 13

The Bavarian Biotech SMEs 14

More about Employment 14

Products and Pipeline 15

Drug development 15

Deals, Cooperations, Mergers, Financing 17-19

Big Deals and Cooperations 17

M&A Activities in Bavaria’s Biotechnology Sector 18

Financing 18

Revenues 19

Summary 19

Portaits of Research Cooperation Networks in Bavaria 20-29

Network IBP – industrial „white“ Biotechnology 20

BayGene – The Bavarian Genome Research Network 22-23

BayImmuNet – Bavarian Immunotherapy Network 24-25

ForNeuroCell – research on adult neural stem cells 26-27

ForZebRA – New Stem Cell Research for the aged 28-29

Company profiles 31-115

in alphabetical order

5

Bavaria has been pursuing a sustainable policy of innova-

tion for many years now and has consistently invested in

research and technology. The excellent Bavarian research

institutions are like a spring constantly bubbling over

with innovative ideas, which makes them an ideal breeding

ground for the biotech sector. But transforming highly

promising ideas into successful products calls for an effec-

tive technology transfer process. This is where our clusters

are making an important contribution – by encouraging

the exchange of know-how between research institutes

and companies, speeding up interdisciplinary knowledge

transfer and establishing contacts for future cooperation

projects.

Framework conditions such as tax law and public health are

also key factors playing an important role in the development

of Bavaria’s biotech industry. Tax incentives for external

equity providers are needed, if we are to continue building

up ambitious high-tech companies in Bavaria also in the

future. Although the situation in the VC market in Germany

did improve slightly last year – at € 570 million 22 percent

more was invested in all branches than in the year before –

it is highly unlikely that we will be able to maintain this level

in 2009. Moreover, the gulf separating us from the USA is

still very wide.

6

Welcome Note for the BiotechnologyReport 2008 of the Biotechnology Cluster

MARTIN ZEILBavarian State Minister of

Economic Affairs, Infrastructure,Transport and Technology

In 2008, one quarter of all German VC investments were

made in Bavaria. This is no mere coincidence: for years,

Bavaria has been pursuing a strategy of boosting private

equity investments with government funds provided by

Bayern Kapital GmbH. In order to help young high-tech

firms overcome their shortage of capital in the current

financial crisis, the € 30 million ‘Clusterfonds Innovation’

programme was launched in March 2009 and can provide

up to € 2 million for companies in the seed and start-up

phase. Further-more, the LfA Bank for the Advancement of

the Bavarian Economy and the EIF European Investment

Fund offer assistance to VC management teams based in

Bavaria within the scope of the umbrella fund initiative to

be launched early in May 2009, which is worth € 50 million.

Despite the economic downturn that was already reaching

serious proportions at the end of last year, the present

report shows that 2008 was a successful year for Bavarian

biotechnology. This is an extremely pleasing result confirming

our policy of past years. We are not, however, going to sit

back and enjoy this success, but will continue to invest in

enhancing biotechnology in Bavaria with the “BayernFIT“

Initiative: the third construction phase of the BioPark

Regensburg, two Fraunhofer project groups (“Chemical and

Biosensor Technology” in Regensburg and “Biogenous

Resources” in Straubing), the promotion of new projects in

the field of “white biotechnology”, the Dementia Research

Centre in Munich-Grosshadern and the construction of a

new Biomedical Center in Martinsried are just a few examples.

These measures will contribute to making Bavaria one of the

leading biotechnology locations in Germany, Europe and

worldwide in the future as well.

“Evolution by Innovation” is the slogan we have selected

for this year’s Annual Report of the Bavarian Biotechnology

Industry. This title is – of course – intended to be a tribute

to Charles Darwin who is celebrated this year for at least

two reasons: 2009 is the 200th anniversary of Charles

Darwin’s birthday and it is also the 150th anniversary of

the first publication of his famous book “On the Origin of

Species”, which marks the beginning of the evolutionary

theory.

You may ask: What has Bavaria and what has biotechnology

to do with Darwin or his theory of evolution? It is by no

means our intention to deprive the British of their Darwin,

but we would nevertheless like to adopt the term evolution

for an industry which is as young as modern biotechnology.

Evolution is incidentally also a theme that is currently

undergoing a renaissance – highly topical in days which are

shaped by the global financial and economic crisis:

7

Preface

PROF. DR.HORST DOMDEY

Managing Director, BavarianBiotechnology Cluster

Companies are established, they evolve and develop the most

intricate networks of connections, both inside and outside

their own economic niches, they adapt their business models

to changing economic framework conditions and, if they fail

to adapt to the changes in the business world, they disappear.

This “play of forces” has existed ever since the ancestors of

contemporary man began using a system of barter for their

first trading activities. To many of us it came as a surprise to

discover that banks, big corporations and even whole states

were beginning to drift into insolvency – or were being dri-

ven into it – by a simultaneous world economic crisis, or

could only be saved using the greatest efforts and through

governmental interventions.

But there are also ecological niches in this global economy –

which brings us back to the biotechnology sector, and espe-

cially to the one in Bavaria. In this specific environment –

Biotech in Bavaria – the focus is very much on innovation and

the search for niches for a new product, a new technology, a

new company. What – in evolutionary terms – is the undirec-

ted mutation, is – in business terms – the “crazy idea” aiming

at a true innovation.

What we really need in this evolutionary process is sufficient

space and a flexible environment for the mutations/ideas

and their resulting innovations. If the right environment is

provided, Bavaria’s biotechnology will not only survive but

will even have a good chance to arise strengthened from

the current dreadful overall crash.

8

A Tribute to

9

It is just twenty years since the evolutionary process – the

creation of innovative and marketable products starting

from and with “crazy ideas” – began in Bavaria´s biotech-

nology sector, from the time when the first companies of

this type were created and established here.

In these past twenty years, the creation, occupation and

defence of a new niche in the health care market – that’s

what most of the Bavarian companies are aiming for – has

passed through all the chapters in Darwin’s book "On the

Origin of Species", from adaptation via selection to the survi-

val of the fittest.

And it is these very “survivors” that are the subject of this

annual report based on a detailed survey of all companies

in the Free State carried out by BioM Biotech Cluster Devel-

opment GmbH. To do this, we distinguished the parameters

specific to each sector and conducted separate surveys for

biotech companies, pharmaceutical companies, contract

research organizations (CROs), contract manufacturing

organizations (CMOs), suppliers and others with activities in

the biotechnology sector. In the case of the biotech

companies, a distinction was once again made between

small and medium-sized companies (SME) having their

headquarters in Bavaria and branch offices and subsidiaries

of national and international biotech companies (biotech-

nology companies, non-SMEs). The term “non-SME” therefore

says nothing about the actual size of this branch office.

For the following report, a biotechnology company has been

defined as a company, which develops and/or manufactures

products on the basis of state-of-the-art molecular biological

methods. But as “conventional” pharmaceutical companies

are increasingly also using such methods, it is often difficult

to differentiate between biotech and pharma. Traditional

phytopharmaceutical companies and manufacturers of

homeopathic products are however not included in this

compilation.

The data forming the basis of this report are based on the

evaluation of a written survey carried out by BioM Biotech

Cluster Development GmbH at the beginning of 2009 of

approx. 320 Life Science companies throughout Bavaria.

Based on the questionnaires returned and intensive followup

telephone calls it was possible to achieve a response rate of

almost 65%.

Additional information was obtained by further individual

investigations. Possible deviations from previously published

figures are the result of additional data obtained in this

survey that also refer to the previous year. The period under

review for this report is the year 2008. Data used in this

report that are not a result of the survey come from other

sources that are mentioned separately on the respective

pages.

Guest articles present current Bavarian research networks

between university and industry. A detailed description of

Bavaria’s Life Science companies provides the reader with all

necessary information about their scope of business and

contact data.

April 2009

Introduction

10

Current Status

Below, we present the results of the company survey

carried out at the end of 2008/beginning of 2009. We look

back at 2008, a year when a crisis in the American real

estate sector developed into a financial crisis with global

impact and now into an outright world economic crisis.

No-one could possibly have foreseen this evolutionary

process, caused only by bad (“subprime”) real estate loans

in the USA. Last year, however, the health industry, i.e.

both the pharmaceutical and the biotechnology sectors,

was still relatively unaffected by this crisis, and indeed,

one could even assume it got off lightly.

With this proviso in mind, namely whether looking at the

past in today’s “troubled times” can also actually say some-

thing about the future, we shall do exactly that: we shall look

back at 2008 as being a very successful year for Bavarian

biotechnology, despite all the growing mood of crisis.

Biotech SMEs and non-SMEs:

In 2008, there were 164 active biotech SMEs in the whole of

Bavaria. 118 of these SME biotech firms are domiciled in the

Munich conurbation, in addition 18 non-SME biotech com-

panies can be found in the Greater Munich Area.

Regensburg on the Danube has the second-largest company

cluster in Bavaria, with 22 biotech companies (SMEs and

non-SMEs) and additionally some 18 companies working in

MedTech, biomaterials and other fields like industrial bio-

technology.

11

The Companies in the BavarianBiotechnology Cluster

Biotech companies(SMEs)

Biotech companies(non-SMEs)

CROs

Pharma companies

Suppliers/CMOs

156157164

number of companies 20 40 60 80 100 120 140 160

2006 (total: 301) 2007 (total: 305) 2008 (total: 319)

BIOTECH/PHARMA COMPANIES IN BAVARIA

There were 15 newly established companies in total (14 in

and around Munich, 1 in Northern Bavaria) and 8 close-

downs. What is particularly striking is the clear increase in

the number of newly established companies compared with

previous years (2006: 4; 2007: 10). But a trend already obser-

ved in recent years is nevertheless continuing: most of the

newly established companies are providing services on the

basis of platform technologies or specific know-how; appa-

rently there are hardly any pure “drug” companies being

established any more; companies are tending to need to

“earn money” straight away, rather than resorting to finan-

cing over the first few years of development. The business

model practised in the biotech sector is therefore increasin-

gly resembling those used in other sectors. For business

ideas irrefutably requiring seed financing, because no other

revenue can be generated, the situation is still difficult even

in Bavaria.

252729

545759

363435

303032

COMPANY CATEGORY ORIGIN

AMSilk GmbH Agriculture, Food, Tech. UniversityEnvironment of Munich (TUM)

AmVac Research GmbH Therapeutics & Diagnostics company spin-off

Baseclick GmbH Devices/Reagents University of Munich (LMU)

BayGenetics Agriculture, Food, University of Environment Bayreuth

BioEPS GmbH Services company spin-off

CellTool GmbH Devices/Reagents n.d.

ChromoTek GmbH Devices/Reagents University of Munich (LMU)

Coriolis Pharma GmbH Preclinical Services University of Munich (LMU)

Intana Bioscience GmbH Preclinical Services company spin-off

MWM Biomodels GmbH Preclinical Services University of Munich (LMU)

NanoTemper GmbH Devices/Reagents University ofMunich (LMU)

Nomad Bioscience GmbH Agriculture, Food, company spin-offEnvironment

OncoLead GmbH & Co. KG Therapeutics & Diagnostics company spin-off

Proteros fragments GmbH Devices/Reagents company spin-off

SiNatur GmbH Therapeutics & Diagnostics company spin-off

COMPANY FOUNDATIONS

12

To stay with the biotech SMEs, the next chart shows the

distribution of specialisations, the fields of business, on

which individual firms have decided to concentrate. The two

main fields of business of these firms in Bavaria are the

development of therapeutics/diagnostics (67 companies)

and the manufacture of devices and reagents (53 companies).

It is therefore not surprising that most people are also

employed in these sectors (see following chapter). More

explicit descriptions of the profiles of these and all the other

Bavarian Life Science companies can be found in the exten-

sive Appendix (s. pages 31f ).

Besides the SMEs, there are 29 branch offices and subsidiaries

of national and international biotechnology companies

(non-SME biotech). The term “non-SME” therefore says

nothing about the actual size of this branch office. One of

these companies for example is Roche Diagnostics in

Penzberg south of Munich. In the ten years since it took over

the Penzberg site in 1998, the Swiss parent company Roche

has invested over € 1.5 billion in new plant and doubled its

work force to over 4,400 employees. In the internal competi-

tions for these investments, Penzberg regularly held its own

against international Roche sites in the USA and Asia:

Penzberg has now established itself as a strategic “centre of

excellence in therapeutic proteins” within the group.

CROs and Pharma:

There are 2 new additions to the group of contract research

organisations (CROs, 59 in 2008), and nearly the same number

of pharmaceutical companies remain as in 2007 (+1). These

companies contribute significantly to the number of

LifeSciences staff in full-time employment, the CROs having

the highest increase in employees of all the categories inve-

stigated (see next chapter).

CMOs, Suppliers, others:

When looking at companies relevant to the biotech industry

from a more general point of view, we must include suppliers,

contract manufacturing organizations (CMOs) and a few

other companies doing contract research. We therefore

included these 32 companies in this survey.

In the field of white or industrial biotechnology, Wacker and

Süd Chemie are two major “global players” operating in

Bavaria. These companies intend to adapt their chemical pro-

duction processes to bring them more into line with biotech-

nological methods and are investing heavily in research and

development with this in mind. Moreover, they are engaged

in networks between science and universities such as the

Bavarian White Biotechnology Network (IBP, see page 20).

There are also 8 biogas companies in Bavaria employing

about 600 persons. These companies however focus rather

on the construction of biogas plants than on biotechnology.

For these reasons biogas companies and the big chemical

companies with only a sideline activity in industrial biotech-

nology are not further included in this survey or in the figures.67

16

8

53

13

7

number of companies 10 20 30 40 50 60

BAVARIAN BIOTECH SMES IN 2008

Therapeutics/ Diagnostics

Agriculture, Food, Environment

Bioinformatics

Devices/Reagents

DNA-/Protein-Analysis

Preclinical Services

13

Employment

Jobs in biotechnology companies

Compared with the previous year, the number of people

employed in all biotechnology companies has risen by 300

to about 8.800 (+ 3,5%). Bavarian biotech SMEs alone cur-

rently employ 3.210 people (previous year: 3.070; +4.6%)

of which around 2.630 work in the greater Munich area.

At the end of 2008, there were 1.040 people employed in

the biotechnology sector in the Regensburg region

(in 2007 it was 895).

In addition to the 3.210 employees in the small and medium-

sized biotechnology companies there are almost 5.610

people working in the branches and subsidiaries of interna-

tional biotechnology companies; nearly 4.470 alone are

working for Roche in Penzberg. In addition, there are a good

9.000 employees working for national and international

pharmaceutical companies. Apart from this, a not inconsid-

erable percentage of local Life Science jobs are offered by

CROs. Approximately another 1.900 people are employed in

this sector. If one looks back a few more years in the deve-

lopment of the CROs in Bavaria, it is quite striking that these

roughly 60 companies have increased their staff numbers

since 2006 by over 20%.

A significant contribution to employment and economic

strength is also made by the “other companies”, which include

suppliers and other service companies as well as production

plants (CMOs), where some 1.920 people are employed.

The total number of employees in the Bavarian Life Science

industry in 2008 came to around 22.000. But this is still not

the full picture, as it does not include the specialised

consulting, finance, patent, marketing and communications

companies, which nevertheless play a very important role in

the development of the corporate landscape and thus of

Bavaria as a top business location.

Biotech (SMEs)

Biotech (non-SMEs)

CROs

Pharma

Suppliers

3.210

5.610

1.900

9.040

1.920

NUMBER OF EMPLOYEES IN THE BAVARIAN BIOTECH CLUSTER

14

Biotech companies(SMEs)

Biotech companies(non-SMEs)

number of employees 2.000 4.000 6.000

2006 2007 2008

DEVELOPMENT OF STAFF NUMBERS INBIOTECH COMPANIES

2.9103.0703.210

5.1705.4505.610

1-10 Employees

11-50 Employees

51-100 Employees

101-250 Employees

61%

27%

6%

6%

SIZE OF BIOTECH SMES BY NUMBEROF EMPLOYEES IN 2008

The Bavarian Biotech SMEs

More about Employment

Looking at the Biotech SMEs in Bavaria, it is very clear that

they focus on the development and marketing of therapeutic

and diagnostic products. Nearly two thirds of the 3.210

employees are working in this area. The other strong focus is

developing of devices and reagents where nearly 800 persons

are employed.

Although the first Bavarian biotech company started twenty

years ago, and by 1996 already 30 companies had been

founded, many of the Bavarian biotech SMEs are less than

10 years old. This youth of many companies can also be seen

in the size of the Bavarian SMEs.

While most of the Bavarian Biotech companies employ

between 1-50 staff members (88% of the SMEs), the majority of

biotech employees work for the 19 greater companies with

staff numbers over 50 (58% of total employees).

The positive development of the staff numbers in the last

few years is shown in a separat figure.

1.887

140

177

764

137

103

number of employees 0 200 400 600 800 1.000 1.200 1.400 1.600 1.800

NUMBER OF EMPLOYEES IN THE BIOTECH SMES IN BAVARIA (2008)

Therapeutics/ Diagnostics

Agriculture, Food, Environment

Bioinformatics

Devices/Reagents

DNA-/Protein-Analysis

Preclinical Services

15

Drug development

Bavaria continues to live up to its leading role in drug deve-

lopment in Germany. In 2003, MediGene from Martinsried

was the company to receive the very first approval for a

drug developed by a German biotech company. In the years

following, MediGene again got approval for 2 more pro-

ducts, which means that, by the end of the year 2008, there

were 3 approved “Bavarian drugs” and 1 further drug in the

final phase of the approval process.

Now, in April 2009, EMEA has approved this drug:

it being the innovative proprietary development of a “tri-

functional antibody” from the Munich based TRION Pharma

company – together with Fresenius Biotech. In other words,

there are by now 4 approved drugs developed by Bavarian

biotechnology companies all originating from the Munich-

Martinsried region, the centre of the Bavarian Biotech

Cluster.

At present (April 2009), clinical development programmes

of the Bavarian SMEs deal with the fields of indication listed

in more detail below.

4SC: Rheumatoid ArthritisAffectis: DepressionAntisense Pharma: GlioblastomaAvontec: Asthma, PsoriasisBavarian Nordic: SmallpoxDoNatur: k.A.IDEA: Onychomycosis, Skin pain and InflammationMediGene: Pancreatic Cancer, Breast Cancer,Rheumatoid Arthritis Micromet: Prostate Cancer, Breast Cancer,Acute Lymphoblastic LeukemiaMorphoSys (with Centocor): ImmunologyScil: Periodontitis Fresenius Biotech/ TRION Pharma: Breast CancerVasopharm: Closed Head InjuryWilex: Pancreatic Cancer, Breast Cancer

Curacyte: Hemoximer®, SepsisDoNatur: MCS-18, PeriarthritisGPC Biotech: Satraplatin®, Prostate Cancer IDEA: Diractin®, OsteoarthritisWilex: Redectane®, PET-ImagingWilex: Rencarex®, Kidney Cancer

MediGene: Eligard®,Prostate Cancer (Europe)MediGene: Veregen®,Genital Warts (USA)MediGene: Oracea™,Rosacea (Europe, sold) Fresenius Biotech/TRION Pharma:Removab®, Malignant Ascites(Europe)

number of drug candidates

100

90

80

70

60

50

40

30

20

10

0

DRUG PIPELINE IN BAVARIA

Preclinic Phase I Phase II Phase III Approved

95

19 19

64

PHA

SE II

PHA

SE II

I

APP

ROVE

D

Products and Pipeline

16

Type of Cooperation

Pfizer and Scil finalize agreement for novel cartilage growth factor

KINAXO Biotechnologies Enters Agreement with Takeda

The US National Cancer Institute Extends its Contract with GENEART – OrderVolume USD 1.9 M

Medtronic and Scil Technology Establish Partnership for Dental BoneRegeneration Therapies

QIAGEN and GENEART Partner to Commercialize Synthetic Mammalian Genes

4SC to acquire Nycomed oncology projects

WILEX and IBA enter into worldwide marketing, distribution and sales agreementon REDECTANE® (CA9-SCAN)

MediGene Sells Licensee Rights to the Drug Oracea® to Galderma

MorphoSys and Galapagos Enter Alliance to Co-develop Novel TherapeuticAntibodies in Bone and Joint Disease

Development of Diabetes II drug leads to € 318 mio in milestone payments

Announcement of Cooperation

Jan 08

Apr 08

Apr 08

Apr 08

May 08

Jun 08

Jun 08

Jul 08

Nov 08

Dec 08

Cooperation Partner

Pfizer

Takeda

National Cancer Institute

Medtronic

Qiagen

Nycomed

IBA

Galderma

Galapagos

Astra Zeneca

COOPERATIONS AND DEALS 2008

17

Big Deals and Cooperations

It is this product pipeline and the excellent technology

platforms that make Bavarian biotechnology companies

especially attractive to national and international part-

ners from industry.

After MorphoSys AG from Martinsried surprised everybody

at the end of 2007 with the megadeal with Novartis (under

which at least € 400 million will flow to Morphosys from

Switzerland in the next ten years), and Idea AG succeeded

in concluding an attractive licence agreement with Alpharma

for over € 124 million, the year 2008 also began with some

positive news.

At the beginning of 2008, Scil Technology in Martinsried was

then also able to report two big deals: Pharmaceutical giant

Pfizer is prepared to pay around € 190 million if the further,

now joint, product developments go according to plan. And

Medtronic, another giant in the field of medical technology,

has entered into a development-collaboration agreement of

an almost similar size with Scil, although they have agreed

not to disclose the financial terms.

Deals, Cooperations, Mergers, Financing

Early in 2008, MediGene received approval for “Oracea”, and

a few months later sold the marketing licence to Galderma

obtaining for its drug a possible total volume of € 32

million.

Along with its close alliance with Novartis, MorphoSys has

been able to develop many more partnerships, for example

with Astellas, Sigma Aldrich, Schering-Plough and Daiichi

Sankyo as well as entering into new ones, for example with

Galapagos from Belgium which was published late in

December 2008 (see some of all the deals and cooperations

in the listing).

The announcement of another “big deal” came in late

December from the North West of Bavaria: the company

Cellmed in Alzenau managed to attract AstraZeneca in a

strategic partnership in the diabetes and obesity field,

worth up to € 320 million at least.

The magnitude of all these deals exceeds by far all other

financing volumes as is described in the next chapter.

MBC Firma/Bayer. Firma

Scil

Kinaxo

Geneart

Scil

Geneart

4SC

Wilex

MediGene

MorphoSys AG

Cellmed AG

18

Mio. €

600

500

400

300

200

100

0

EXTERNAL FINANCING AND DEALS

2006 2007

Follow-OnIPOVC + Silent PartnershipsFinancing “on demand”closed deals (dotted line)in the respective year only

151,4

76,7

78,2

42,2

139,6

34

533

2008

84,0

57,2

61,2

540

Financing

Successful financing rounds were completed by Freising’s

Pieris (€ 25 million), Suppremol (€ 16 million) and Corimmun

(€ 5 million), all from Martinsried. And some publicly listed

companies from Martinsried actually even managed to

increase their capital in 2008, namely 4SC (€ 30 million) and

Micromet (€ 30 million).

Virologik of Erlangen acquired financing of € 7 million,

and many got seed funds in the 6 to 7-digit range such as

Sirion and Lophius. Interestingly, the companies doubled

the volume of support funding (grants) provided from

governmental or federal sources to € 16 million compared

with 2007.

If all the financing is taken together, a total of around € 120

million is obtained for the Bavarian biotech companies, which

is not much these days, when everyone is calling for one

hundred billion dollar rescue packages, but it is not too bad

in the present so-called “real economy”. VC-investments in

LifeSciences in Germany account for about € 140 million in

2008 (BVK, German Private Equity and Venture Capital

Association) nearly half of it went into Bavarian companies.

Two companies from Martinsried managed to open a new

chapter in financing models: namely “financing on demand”.

Micromet has been promised funds of nearly € 60 million,

whenever the companies thinks it might need them.

MediGene managed to secure itself € 25 million under this

“financing on demand” model.

In spring 2008, Till Photonics from Gräfelfing near Munich, a

company whose core competence is molecular imaging, was

taken over by Agilent Technologies. And the biotech compa-

ny U3 Pharma, Martinsried, was taken over by Japan’s third

largest pharmaceutical company Daiichi Sankyo for around

€ 150 million.

The two takeovers are having very positive effects on the

location: the companies’ know-how has not simply been

“sold off ”, because the two big corporations are determined

to establish a base in and close to the Martinsried biotech-

nology centre in this way. This means that the companies

and their know-how will remain at the location and will

definitely be developed further by their new parent group.

And Bavarian companies themselves have been active in

gaining a foothold: 4SC of Martinsried bought 4% of Nexigen

(Bonn, Germany) with the option of a complete takeover.

M&A Activities in Bavaria’s Biotechnology Sector

The Bavarian biotechnology industry is also proving to be attractive to international companies on the lookout for reasona-

ble supplements to their portfolio. In 2008, two companies from Munich’s south attracted the attention of company scouts,

ultimately leading to company takeovers:

19

161 192

2006

REVENUES TOTAL IN MIO. €, LISTED COMPANIES

Summary

The Bavarian biotech industry can look back on a history

that has developed over just two decades, a history with

more ups than downs.

Within this period of about 20 years – in evolutionary time-

scales not even a blink of an eye –, an industry employing

around 9.000 people (21.000 including pharma and suppliers)

has established itself and has been able to build up a

tightly-knit network of interrelationships, not only within

itself, but also at international level. Despite the most adverse

conditions in 2008, a year of crisis, these companies have

shown remarkable stability and even positive developments.

If it was possible to look at the biotechnology industry in

isolation ignoring all the surrounding sectors, then there

would certainly be no question of a crisis here. However, it is

perfectly possible that even economic niches might be hit

by the offshoots of the waves of crisis spreading like a

tsunami – and Bavarian biotechnology companies could yet

be struck by a new evolutionary challenge.

But the Bavarian biotech companies seem to be able to

deal successfully with any difficult times the future may

hold in store - according to our slogan:

evolution by innovation!

2008

2007

154

Revenues

For comparison, the figure on the right focus on the

published business data of Bavarian biotechnology com-

panies quoted on the stock exchange.

These are:

4SC, Geneart, GPC, MediGene, Micromet, MorphoSys, MWG

and Wilex.

Their stated sales revenues for 2007 accounted for € 154

million and add up for 2008 to € 192 million, which is a plus

of nearly 20%. The R&D investments by these listed compa-

nies total € 144 million.

62% of all the other biotech SMEs answered our question-

naire concerning their revenues. It reveals about € 150 million

in total revenues and € 110 million for R&D investments.

The real picture of all the revenues the Bavarian Biotech

SMEs account for in 2008 will therefore approximatly sum

up to between € 350 to € 450 million.

20

Network White Biotechnology

The Network IBP (“Industrial Processes with Biogenic Buil-

ding Blocks and Performance Proteins”) is a winner of the

competition “BioIndustry 2021” of the Federal Ministry of

Education and Research (BMBF). It is a consortium of

academic and industrial partner who brought together

their complementary skills to develop new processes and

products in the sector of White Biotechnology.

IBP’s focus is manufacturing of chemicals from renewable

feedstock by using novel implementation strategies. To this

end, complex lignocellulosic material is decomposed by a

unique method called “sequential enzymatic hydrolysis”

(“SEH”), which avoids problems usually associated with total

hydrolysis, like heterogeneous mixtures of plant components.

By this process, the feedstock is supposed to yield rather

pure biogenic building blocks. These are further refined to

products, like acetate or ethanol, by efficient methods like

anaerobic fermentation, metabolic engineering and

“in process chemistry”. The conversion and separation of the

substances occur via “performance proteins”, e. g. technical

enzymes. The Network IBP strivers to exploit the entire plant

material like lignin, proteins and secondary metabolites –

not just carbohydrates.

By its concept, the Network IBP will demonstrate an economic

production of hitherto only petro-chemically manufactured

biogenic building blocks and basic chemicals. Moreover,

IBP establishes a sustainable “3rd generation” biorefinery:

There is no competition with food resources and fewer

impurities of intermediates and products may be expected.

IBP creates value through production-embedded measures

for the protection of the environment, as opposed to

aftercare. These benefits result in clear economic advantages

and increase of performance and competitiveness of the

participating network partners. IBP supports the development

of White Biotechnology from a niche technology to an

economically and ecologically efficient platform technology

for the chemical industry.

Portaits of Research Cooperation Networks in Bavaria

Network White Biotechnology

For its technical projects, IBP gains a subsidy of € 10 million

from BMBF and the Ministry of Economic Affairs, Infrastruc-

ture, Transport and Technology of the Free State of Bavaria.

This amount is doubled by the industry.

For the administrative management of the Network IBP and

for the more general challenge to strengthen White

Biotechnology, BioM WB GmbH was founded in June 2008 by

the “Association for the Promotion of White Biotechnology in

Bavaria”. BioM WB GmbH pursues the establishment of an

international network of White Biotechnology centred in

Bavaria. The company is funded by the Ministry of Economic

Affairs, Infrastructure, Transport and Technology of the Free

State of Bavaria, by the Federal Ministry of Education and

Research (BMBF) as well as by the globally operating chemical

companies Wacker Chemie AG and Süd-Chemie AG.

BioM WB GmbH works closely with the Bavarian Biotech-

nology Cluster and supports the “Cluster-Initiative” of the

Bavarian Government.

The concept of research cooperations for interdisciplinary and close to application research projects has a long tradition in

Bavaria. In the last twenty years there were more than ten specific research cooperations in the LifeSciences coordinated by

the Bavarian Research Alliance. Two of the still running programs you can find in the latter part of this survey (ForNeuroCell

and ForZeBRA). But there are also other main research cooperation projects that are seperatly managed, of these we present

the “White Biotechnology”, the Bavarian Genome Research and the Bavarian Immunotherapy Networks on the next pages.

CONTACT

BioM WB GmbH

Prof. Dr. Haralabos Zorbas

CEO and Spokesman of Network IBP, IZB West

Am Klopferspitz 19a

D-82152 Martinsried

Phone: +49 (0)89-54 04 54 714

Fax: +49 (0)89-54 04 54 715

E-Mail: Haralabos.Zorbas@BioM-WB.com

Internet: www.biom-wb.com

21

22

For these reasons, the Bavarian State Ministry of Sciences,

Research and the Arts provided € 27 million in total for

seven years to set the starting signal for the foundation of a

unique network, which is intended to support outstanding

academic research in the field of functional genome research.

Initially, five projects met the standards of excellence set by

an international scientific advisory board and, subsequently,

received funding for seven years. An additional four projects

were selected in 2006. Since then, financial support of one

of the nine BayGene projects has ceased, but the project

enjoys continued membership status. Three new projects

were selected in February 2009 and are expected to receive

funding for a period of five years starting in May 2009.

Scientific Projects

Molecular pathogenesis of hereditary cerebrovascular

malformations of the central nervous system

Prof. Dr. Ute Felbor, University Würzburg

Functional genomics of herpes viruses: Identification of

pathogen-specific events by systems biology-based

approaches

Prof. Dr. Dr. Jürgen Haas, LMU München

Regulatory networks of intracellular membrane modula-

tion: Signalling complexes of the Spir actin nucleation

factors and the RasGEF very-KIND

Prof. Dr. Eugen Kerkhoff, University of Regensburg

Functional genomics and therapy of early-disseminated

tumor cells: A novel approach to the prevention of meta-

stasis

Prof. Dr. Christoph Klein, University of Regensburg

Molecular mechanisms of chromatin dynamics

Prof. Dr. Gernot Längst, University of Regensburg

Experimental characterization of micro RNA- interaction

networks

Dr. Gunter Meister, Max-Planck-Institute for Biochemy,

Martinsried

BayGene –The Bavarian Genome Research Network

Genetic protein folding defects: Development of

pharmacotherapeutic strategies

Prof. Dr. Ania Muntau, LMU München

Antibody mediated effector function and control

mechanisms for B-cell tolerance in the humanised mouse

Prof. Dr. Falk Nimmerjahn, University Erlangen-Nürnberg

Functional genomics of degenerative, metabolic, and

malign diseases

Prof. Dr. Peter J. Oefner, University of Regensburg

(Senior Project)

Modelling signal transduction networks and their impaired

function in malignant tumours

Prof. Dr. Rainer Spang, University of Regensburg

Molecular imaging: An instrument for functional proteomics

Prof. Dr. Hans Jürgen Wester, TU München

The Bavarian Genome Research Network faces up to the

challenges of this promising area: outstanding research pro-

jects in the domain of genome research are supported and

cooperate amongst each other using this newly created net-

work BayGene. To realize their visions, aims and strategies,

scientists will coordinate their efforts crossing local bounda-

ries in this pan-Bavarian network to increase the efficiency

and flexibility of their research and to achieve its goals

faster.

Summary of Achievements

The members of the BayGene program have filed seven

patent applications and published a total of 120 papers since

the beginning of funding. Of the publications, 38 appeared

in scientific journals rated with an impact factor >10, amongst

them the Annual Reviews of Immunology, Nature, Nature

Reviews Immunology, Nature Cell Biology, Science and

Cancer Cell. In addition to their BayGene funding, the net-

work’s projects received an additional € 14.8 million in fun-

ding from other grants. These achievements, a market

authorisation of a drug and the formation of a start-up

The Bavarian Genome Research Network coordinates leading research projects in the field of functional genome research in

Bavaria. Based on a better understanding of gene functions, interactions and regulatory mechanisms, significant progress

can be expected in the diagnosis and treatment of illnesses such as cancer and diabetes. The scientific and economic possibi-

lities of functional genome research will significantly change industry and society in the 21st century.

23

CONTACT

BayGene Gene Center Munich

Main Office: Dr. Ulrike Kaltenhauser

Feodor-Lynen-Str. 25

D-81377 Munich

Phone: +49 (0)89-8 59 50 54

Fax: +49 (0)89-85 66 16 80

E-Mail: baygene@lmb.uni-muenchen.de

Internet: www.baygene.de

company justify impressively the investment made by the

Bavarian State Ministry of Sciences, Research and the Arts

into cutting-edge genome research. Integration of regional

industries into the network structure is one of BayGene's

aims. For this reason, eleven Bavarian biotechnology compa-

nies are affiliated with BayGene.

This research effort initiated and funded by the Bavarian

Government is an important step in maintaining Bavaria’s

leading position in the national economic and international

scientific competition.

Scientific advisory board:

Chairman: Professor Dr. Fritz Melchers, Berlin

Members:

Dr. Carmen Buchrieser, Paris

Professor Dr. Manfred Dierich, Innsbruck

Professor Dr. Lutz Gissmann, Heidelberg

Professor Dr. Michael Hallek, Cologne

Professor Dr. Jürgen Hescheler, Cologne

Professor Dr. Lukas Huber, Innsbruck

Professor Dr. Mathias Müller, Vienna

Professor Dr. Sabine Werner, Zurich

Scientific director:

Professor Dr. Horst Domdey,

Martinsried

Managing director:

Dr. Ulrike Kaltenhauser,

Munich

24

Who we are

BayImmuNet is a Bavaria-wide research network that is

focused on the translation of innovative immunotherapeutic

strategies into early clinical trials. Network members are

scientists and research groups at the five Bavarian universities

with medical faculties that perform translational research

projects within BayImmunNet. Network partners are phar-

maceutical and biotech companies interested in novel

immunotherapies. BayImmuNet and its projects are suppor-

ted by the Bavarian State Government within the “BayernFIT”

programme, up to a total of € 10 million. The five participa-

ting universities contribute up to € 4 million. Currently sup-

ported research projects explore novel therapies in trans-

plantation medicine, cancer treatment and auto immune

diseases.

AIMS

Our motto is: „Collaborate in research! Share knowledge!

Conquer disease!“ Thus, it is our common goal to…

intensify the collaboration of academic centres and to

promote partnerships with pharmaceutical and biotech

companies.

accelerate the transfer of research findings into early

clinical trials (“translational medicine”).

develop therapeutic reagents suited for clinical

applications.

Areas of activity

We support renowned scientists in the field of translational

immunotherapy in Bavaria by financing research groups.

We provide financial support for talented young scientists

who contribute to the development of new therapies.

We facilitate collaborations between scientists and research

centres in Bavaria through the exchange of know-how and

technologies, joint clinical studies, open access to specialized

laboratory facilities, etc. We promote joint ventures between

science and business to accelerate the transfer of research

findings into clinical practice on the basis of mutual coope-

ration agreements.

Projects

Funding by the Free State of Bavaria enables BayImmuNet to

support…

five research groups at the university hospitals in

Erlangen, Munich, Regensburg and Würzburg

preclinical and clinical trials to develop and apply new

immunotherapeutic agents

the "José Carreras Centre for Somatic Cell Therapy"

(GMP facility) at the Regensburg University Hospital.

All projects are assessed by an independent scientific advi-

sory committee and supported and supervised by a co-ordi-

nating committee.

BayImmuNet’s “Translationalimmunotherapy” project teams

In September 2008, five “translational immunotherapy”

project teams started their work studying immunotherapy

approaches in the fight against tumour diseases and infections.

Project team at the Erlangen University Hospital:

“Adoptive T-cell Therapy for the Treatment of Patients with

Cancer”. This project aims to develop new strategies for the

priming, selection and expansion of antigen-specific effector

T cells under the guidelines of good manufacturing procedure

(GMP) that will be used for adoptive T-cell therapy in patients

with solid and hematologic malignancies.

Project management: Professor Dr. med. Andreas Mackensen

Project team at the Munich University Hospital (Grosshadern):

“Immunotherapy of high-risk acute myeloid leukaemia using

dendritic cell vaccination”. The central goal of this project is

to develop a multiplex DC vaccine for immunotherapy of

AML and to implement a clinical phase I/II study in

high-risk patients. The vaccine will utilize RNA-pul-

sed mature dendritic cells that have the capacity

to secrete bio-logically active IL-12p70, in order

to activate both Th1-polarized adaptive and

innate immune responses.

Project management:

PD Dr. med. Marion Subklewe

BayImmuNet –Bavarian Immunotherapy Network

25

Project team at the Munich Technical University Hospital:

“Development of adoptive T-cell therapies in patients with

Her2/over-expressing breast cancer”. The identification of

HER2-specific T-cell receptors (TCR) derived from T cells of

patients with long-lasting specific T-cell immunity and the

potential clinical response will provide the basis for the deve-

lopment of future treatment modalities with the objective of

reaching a broader patient population while reducing costs.

Project management: Dr. med. Angela Krackhardt

Project team at the Regensburg University Hospital:

“Adoptive transfer of CD4+CD25+ regulatory T cells for tole-

rance induction”. Graft-versus-host disease (GVHD) is a major

complication after allogeneic stem cell transplantation (SCT)

and is the main cause of its high treatment-related morbidity

and mortality. We previously demonstrated that the adopti-

ve transfer of donor-derived natural CD4+CD25+Foxp3+

regulatory T cells (Treg) does not induce GVHD in murine

disease models, but prevents GVHD induced by conventional

T cells. We now aim to extend these translational studies to

establish GMP-compatible in vitro expansion protocols for

human Treg cells and to perform a phase I-II dose-finding

and efficacy study in stem cell recipients.

Project management: Professor Dr. med. Matthias Edinger

Project team at the Würzburg University Hospital:

“Development of an immunotherapy protocol for the pre-

vention and treatment of Aspergillus fumigatus infection”.

Mice can be protected from a lethal A. fumigatus challenge

by transfer of Th1 T-cells, by DC vaccination as well as by

induction of Treg T cells. Our group has identified in human

immunodominant A. fumigatus derived T-cell epitopes as

well as an A.fumigatus derived protein, which can condition

DCs for better inflammatory response.

Project management: Dr. med. Max Topp

CONTACT

BayImmuNet

c/o Regensburg University Hospital

Franz-Josef-Strauß-Allee 11

D-93053 Regensburg

Scientific Director:

Prof. Dr. Reinhard Andreesen

Phone: +49 (0)941-9 44-55 01

Fax: +49 (0)941-9 44-55 02

E-Mail: reinhard.andreesen@klinik.uni-regensburg.de

Managing Director:

Dr. Isolde Schäfer

Phone: +49 (0)941-9 44-53 401

Fax: +49 (0)941-9 44-53 42

E-Mail: info@bayimmunet.de

Internet: www.bayimmunet.de

26

The Bavarian State Ministry of Science, Research and the

Arts is funding a research network with focus on adult neural

stem cells ForNeuroCell (www.bayfor.org/forneurocell).

In ForNeuroCell, groups of the University of Regensburg, the

Helmholtz Center Munich – National Research Center for

Environment and Health, the Friedrich-Alexander-University

of Erlangen-Nuremberg, the Ludwig-Maximlians-University

Munich and the Technical University of Munich work together

on the following research topics.

Reprogramming of neural progenitor cells:

Development of a methodology to differentiate human

astrocytes into functional neurons

Characterizing and establishing of adult human neural

stem cells and identification of signaling pathways and

receptor structures that may serve as targets to modulate

neural stem cells:

Characterization of adult stem cells of the human

hippocampus

Identification of signaling-pathways regulating adult

neural stem cell maintenance

Identification of signaling pathways in the induction,

differentiation and maintenance of dopaminergic neurons

in the embryonic and adult mibrain

Characterization and mobilization of adult neural stem

cells to induce cellular regeneration in Parkinson’s disease

Co-transplantation of adult neural progenitor cells and

mesenchymal stromal cells to promote axonal

regeneration und remyelination in the injured spinal cord

Establishing and implementing innovative imaging techni-

ques to detect endogenous neurogenesis and grafted cells:

In vivo cell tracking by magnetic resonance tomography

(MRT) of adult neural stem cells and brain parenchyma

response to stem cell transplantation

Optical and MR imaging tools to track neural stem and

precursor cells in adult brain

ForNeuroCell –research on adult neural stem cells

Neurodegenerative diseases of the brain are among the greatest therapeutic socio-economic challenges to modern industria-

lized societies. The discovery of multipotent neural stem cells within the adult brain has generated great hope in finding ways

to use the regenerative potential of these cells to develop novel therapeutic strategies for neurodegenerative diseases as well

as traumatic injuries of the spinal cord or the head.

27

CONTACT

ForNeuroCell

Physiological Institute

Physiologic Genomics

Dr. Rosi Lederer

Pettenkoferstr.12

D-80336 Munich

Phone: +49 (0)89-2180 75258

+49 (0)89-3187 3864

Fax: +49 (0)89-2180 75216

E-Mail: rosi.lederer@med.uni-muenchen.de,

forneurocell@klinik.uni-regensburg.de

Figure 1:Adult hippocampal stem cells. Figure (1) shows the dentate gyrus. Stem cells arelocated in a narrow stripe of cells between the granule cell layer (GL) and thehilus. This area is called the subgranular zone (SGZ). Adult hippocampal stemcells exhibit astrocytic properties and are characterized by nuclear expression ofthe transcription factor Sox2 (in red) and glial fibrillary acidic protein (GFAP, ingreen) which is present in the typical radial process of stem cells. Non stem cellastrocytes also express SOX2 and GFAP but lack the characteristic radial process,spanning the granule layer. Exemplary stem cells (white arrow head) are shown inhigher magnification in the inset.

Figure 2:Immature neurons. Adult hippocampal stem cells have the unique capability to give rise tonew granule neurons. Figure (2) shows immature neurons, called neuroblasts. These cellsare characterized by their expression of the microtubuli associated protein Doublecortin(DCX, in green). The expression of the transcription-factor SOX2 (in red) is down-regulatedin neuroblasts. During their further differentiation into mature granule neurons, neurob-lasts stop to proliferate and become post-mitotic. The whole differentiation process of ahippocampal stem cell into a mature granule cell takes about one month.

Pre-clinical testing in acuteand chronic lesion models

This consortium is highly suitable for working on these

questions as the following technological resources are

well established:

state-of-the-art molecular biology

innovative cell biology

pre-clinical animal models

current imaging technologies

availability of human biomaterial

ForNeuroCell aims at advancing basic research on biotech-

nological development of adult stem cells of the nervous

system in order to achieve recovery of damaged brain

regions.

A series of damages occur in the genetic information of all body cells during ageing. Therefore the complex process of on-going

tissue regeneration breaks down. This eventually leads to degeneration – the progressive loss of function of individual organs or

of the overall organism. Typical degenerative diseases in the skeletal and musculoskeletal system are osteoporosis and osteopo-

rosis related fractures, as well as osteoarthrosis, intervertebral disc deterioration and degeneration of tendons. Direct costs of

more than € 36 billion accrue for this disease in Germany annually, which corresponds to approximately 16% of the overall costs

for diseases in the Federal Republic of Germany. Due to ever-increasing life-expectancy, all experts anticipate a considerable

increase in the aforementioned degenerative diseases and their respective related costs.

Platform 2: Cell Application/Cell-tracking

Improvement in the application of stem cells into defect

sites using new injectable systems and carrier materials

Tracking of the introduced stem cells and cell-seeded con-

structs by means of complex cell-tracking in vivo with the

aid of image guided procedures such as nuclear imaging

techniques, magnetic resonance tomography and optical

procedures

Quantitative and qualitative monitoring of the applied cells

is the decisive precondition for an assessment of the inno-

vative forms of innovative stem cell-based therapeutic stra-

tegies

Platform 3: Bio-evaluation/genetically modified large animal

models

Production of genetically modified, immuno-deficient pigs

as model organisms using innovative techniques of gene

transfer

Examination of the efficiency and safety of therapeutic

approaches on the basis of human cells or tissue constructs

in the large animal model

Use of the pig model for pre-clinical evaluation studies

Economic Applications:

Enterprises should evolve out of the three platforms, which test

and evaluate new therapy concepts from the molecular level to

animal models. Following this, their final goal is to commercially

offer these new treatment regimes for degenerative dise-

ases in the aged. Furthermore, detection and eva-

luation of new targets is possible for pharma-

ceuticals supporting the healing of mus-

culoskeletal diseases. This can also be

marketed through early integration

with large industrial enterprises.

28

ForZebRA –New Stem Cell Research for the agedcell-based regeneration of the musculoskeletal system

Indeed, many advances have been made in the treatment of

degenerative diseases, such as the development of artificial

joints or the implementation of drug therapy for osteoporosis.

However, none of the currently used therapeutic procedures

have been able to rectify damage within the tissue; rather

they can merely limit it. In the Research Cooperation

ForZebRA the expertise of nine university partners and twelve

industrial partners is consolidated, in order to examine in

detail degenerative diseases such as osteoporosis, osteoarthri-

tis and tendinopathies in the aged, and to develop innovative

therapeutic strategies, such as stem cell-based therapies.

ForZebRA is divided thematically into three platforms: cell-bio-

logy/genomics, cell-application/cell-tracking and bio-evalua-

tion/genetically modified large animal models. This wide

range of contents and methods allows a detailed analysis of

both degenerative processes and the induction of regenera-

tion during ageing. Concurrently, monitoring of new therapy

concepts can be conducted effectively. The particular point of

scientific interest is the special situation in old patients.

Research Topics

Platform 1: Cell Biology/Genomics

Development of a data-bank for the comparative represen-

tation of the transcriptome of younger, healthier mesenchy-

mal stem cells (MSC) and aged MSCs for detection of key

genetic degenerative diseases and induction of regenera-

tion for the aged

Development of procedures for the inspection of stem cell

quality, and avoidance of ageing in the utilized stem cells

by means of modulation of the gene expression

Examination of changes in the gene expression after

mechanical manipulation of cells and tissues

Partners

Academic Partners:

Clinic of the LMU Munich, Surgical Clinic and Poly-Clinic-

“Innenstadt”, Experimental Surgery and Regenerative

Medicine (ExperiMed)

Clinic of the LMU Munich, Clinic and Poly-Clinic for Nuclear

Medicine – “Innenstadt” and “Grosshadern”

Forschungszentrum Magnet-Resonanz-Bayern e.V. (MRB)

and University of Würzburg, Physical Institute, Experimental

Physics 5

Gene Centre of the LMU Munich, Chair for Molecular Animal

Husbandry and Bio-Technology and Laboratory for

Functional Genome Analysis (LAFUGA)

LMU Munich, Department Pharmacy, Pharmaceutical

Technology and Bio-Pharmacy

Paracelsus University Salzburg and BG Trauma surgery,

Murnau

TU Munich, Scientific Centre Weihenstephan, Chair for Bio-

Technology of Animals

University of Ulm, Institute for Trauma Surgery Research and

Bio-Mechanics

University of Würzburg, Orthopaedic Clinic in König-Ludwig-

Haus, Orthopaedic Centre for Musculoskeletal Research

Industrial Partners:

Arthrex GmbH, Karlsfeld

BIONORICA AG, Neumarkt

BioStemTec, Munich

Coriolis Pharma, Munich

LivImplant, Munich

MWM Biomodels, Tiefenbach

Novartis Deutschland GmbH, Nuremberg

PolyMaterials AG, Kaufbeuren

PreSens GmbH, Regensburg

Rapid Biomedical, Rimpar

Siemens Medical Solutions AG, Erlangen

Tutogen Medical GmbH, Neunkirchen am Brand

29

CONTACT

Spokesperson: Prof. Dr. med. Wolf Mutschler; Surgical Clinic

and Poly-Clinic-“Innenstadt”, Clinic of the University of Munich

Assistant Spokesperson: Prof. Dr. med. Franz Jakob;

Orthopaedic Centre for Musculoskeletal Research, Chair for

Orthopaedics and Orthopaedic Clinic in König-Ludwig-Haus

Managing Director: Dr. rer. nat. Sabine Ott; Surgical Clinic and

Poly-Clinic-“Innenstadt”, Clinic of the University of Munich

Nußbaumstr. 20

D-80336 Munich

Phone: +49 (0)89-5160-7557

Fax: +49 (0)89-5160-5482

E-Mail:

ForZebRA-Geschaeftsstelle@med.uni-muenchen.de

Internet: www.bayfor.org/forzebra

Investigation of new therapies for degenerative diseases of bone, cartilage and tendon

Funded by the Bavarian Research Foundation with 1.77 m €. Total amount of3.50 m €.

CoNtACt

Fördergesellschaft IZB mbH

Am Klopferspitz 19

82152 Martinsried

Phone: +49 (0)89-700 656 70

Internet: www.izb-online.de

CoNtACt

BioPark regensburg GmbH

Dr. thomas Diefenthal

Josef-Engert-Str. 9

D 93053 regensburg

Phone: +49 (0)941 920 460

Fax: +49 (0)941 920 4624

Internet: www.bioregio-regensburg.de

CoNtACt

IGZ BioMed/ZmK

Dr. Gerald Böhm

Friedrich-Bergius-ring 15

D-97076 Würzburg

Phone: +49 (0)931 270 62 94

Internet: www.igz.wuerzburg.de

Biotech Incubators in Bavaria